Once clinical studies have demonstrated the effectiveness and safety of a new intervention in the area of health assistance, the key question for payers is what benefits this could effectively offer patients in real conditions. How is the clinical improvement perceived by the patients? Are the patients who are treated with the drug in actual practice the same as those included in the clinical studies?

To respond effectively it is necessary to resort to Outcome Research, which has the goal of defining and carrying out health economic studies to support national and/or local Health Technology Assessment (HTA) activities.

Through direct exploration, we help customers understand what drives the payers’ decision-making process. We express and test a clear Value Story of the product/portfolio, producing the relevant evidence and support tools.

Key activities:

Analysis and Definition Support

Study of the scenario
Reconstruction of the national and local legislative and regulatory framework

Monitoring tools
Regional/local analysis and mapping of stakeholders (clinicians and payers)

Access strategy definition
Definition and execution of regional access plans (inclusions in PTOR/PTO (Regional Hospital Therapeutic Formulary/Hospital Therapeutic Formulary), Recommendations of use after HTA activities)

Value proposition development
Development of economic analyses which strengthen the Value Proposition (CEA-cost effective analysis, Cost-Utility)

Activity support
Mapping, analysis and implementation of corrective actions or facilitation in drawing up Diagnostic, therapeutic care pathways (DTP)

Real World Data Analysis
Support to the value of the drug or device through:

  • analysis of large administrative databases
  • investigation of patients
  • development and validation of Patient reported outcomes and similar
  • analysis of microcosting-DRG (Diagnostic Related Groups)

Request information

Fill out the form to be re-contacted